期刊
ESC HEART FAILURE
卷 5, 期 1, 页码 184-188出版社
WILEY PERIODICALS, INC
DOI: 10.1002/ehf2.12219
关键词
Cardiomyopathy; Systolic dysfunction; Inodilator therapy; Heart failure; Reduced ejection fraction
资金
- National Institutes of Health Clinical Center
Refractory heart failure typically requires costly long-term, continuous intravenous inodilator infusions while patients await mechanical circulatory support or cardiac transplantation. The combined angiotensin receptor blocker-neprilysin inhibitor, sacubitril/valsartan, is a novel therapy that can increase levels of endogenous vasoactive peptides. This therapy has been recommended as an alternative agent in patients with chronic heart failure with reduced ejection fraction and New York Heart Association class II-III symptoms. Here, we report a case of a patient with refractory stage D heart failure with reduced ejection fraction who was successfully weaned off continuous intravenous inodilator support using sacubitril/valsartan after prior failed attempts using standard therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据